Eur Rev Med Pharmacol Sci 2022; 26 (16): 5829-5834

DOI: 10.26355/eurrev_202208_29522

Application of XOLAIR® (Omalizumab) in adolescent refractory chest tightness variant asthma

B. Ding, Y.-Q. Li, Y. Lai, Y.-M. Lu

Department of Pediatrics, Renji Hospital Affiliated to ShangHai JiaoTong University School of Medicine, Shanghai, China. dingbo1986515@gmail.com


BACKGROUND: Asthma can manifest in a variety of clinical phenotypes like cough variant asthma, chest tightness variant asthma (CTVA), and masked asthma. Patients with CTVA usually have a singular or primary complaint of chest tightness, which is often overlooked or misdiagnosed due to the lack of characteristic asthma symptoms. We hereby report a case of CTVA managed by omalizumab.

CASE REPORT: A 15-year-old female patient reported to us with repeated coughing persisting for 3 weeks. Initial treatment with standard asthma drugs had minimal effect. Later during the disease, chest tightness became the primary symptom, and she was managed with steroids, β2 receptor agonists, and leukotriene receptor agonists but without complete relief. Based on clinical signs and symptoms, the response to baseline drugs, and results of bronchial provocation test, the diagnosis was revised to CTVA, and the patient was started on Omalizumab in addition to baseline drugs, which significantly improved her condition.

CONCLUSIONS: CTVA is difficult to diagnose due to its insidious symptoms and poor characteristics. Improper treatment can lead to uncontrolled disease, negative psychological issues, and reduced quality of life. Comprehensive assessment of children’s airway inflammation level, lung function, bronchial provocation test, and responsiveness to drug therapy should be performed for accurate diagnosis. Omalizumab in combination with standard drugs can significantly improve the outcomes of CTVA.

Free PDF Download

To cite this article

B. Ding, Y.-Q. Li, Y. Lai, Y.-M. Lu
Application of XOLAIR® (Omalizumab) in adolescent refractory chest tightness variant asthma

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 16
Pages: 5829-5834
DOI: 10.26355/eurrev_202208_29522